Osteoporosis Screening in the Reconstructive Urology & Urogynecology Patient
Reconstructive practices care for patients at risk of bone loss from menopause, GnRH therapy, aromatase inhibitors, androgen deprivation and systemic glucocorticoids used for other conditions. Long-term oral glucocorticoids are not recommended as routine IC/BPS or Hunner-lesion therapy.[13][1] Vertebral fractures can impair mobility and complicate operative positioning; hip fractures in this population carry substantial morbidity and mortality. The 2025 USPSTF reaffirmed a Grade B recommendation for dual-energy x-ray absorptiometry (DXA) screening in all postmenopausal women aged ≥ 65 years, and in younger postmenopausal women with elevated fracture risk — making osteoporosis screening a core component of the comprehensive preventative-care visit.[2]
Who to Screen
Universal threshold: ≥ 65 years
DXA screening is recommended for all postmenopausal women aged ≥ 65 years, without requiring additional risk factor assessment.[2]
Younger postmenopausal women (< 65 years)
A practical two-step approach applies to younger postmenopausal women:
- Identify clinical risk factors such as low weight, parental hip fracture, smoking or excess alcohol.
- If risk factors are present, use a validated osteoporosis/fracture-risk tool to decide on DXA. USPSTF 2025 does not define 9.3% FRAX as a screening threshold; that figure illustrates a reference patient’s risk. Do not confuse screening decisions with thresholds for pharmacologic treatment.[2][3]
Risk factors warranting earlier screening
| Category | Examples |
|---|---|
| GU / gynecologic treatments | GnRH agonists (preoperative priming, endometriosis, fibroids), aromatase inhibitors (breast cancer survivors), prolonged estrogen deprivation |
| Other medications | Systemic glucocorticoids ≥2.5 mg/day prednisone-equivalent for >3 months warrant dedicated risk assessment, anticonvulsants, medroxyprogesterone acetate |
| Anthropometric | Low body weight (<127 lb / 57.6 kg), BMI <20 kg/m² |
| Lifestyle | Current smoking, alcohol >3 drinks/day |
| Medical conditions | Rheumatoid arthritis, type 1 or 2 diabetes, hyperparathyroidism, celiac disease / malabsorption syndromes |
| Family history | Parental history of hip fracture |
| Reproductive | Premature menopause (<45 years), prolonged amenorrhea |
GnRH therapy: Bone loss, treatment-duration limits and add-back depend on the product and indication. Leuprolide endometriosis labeling supports norethindrone add-back and limits total therapy with add-back to 12 months, with BMD assessment before retreatment; its three-month fibroid/anemia indication differs. Do not automatically prescribe estrogen-progestin or a bisphosphonate for every short course.[11]
Diagnosis
In postmenopausal women and men aged 50 or older, osteoporosis assessment includes:[1][7]
- DXA T score ≤ −2.5 at the lumbar spine, total hip, or femoral neck
- Hip or vertebral fragility fracture supports treatment regardless of BMD. Fractures at other sites require assessment of BMD, mechanism and clinical risk rather than an automatic diagnosis from any fracture.[9]
Osteopenia is defined as a T score between −1.0 and −2.5; this range requires FRAX integration to determine treatment need.
T scores are compared to a young-adult reference population (female, age 20–29); Z scores compare with age-matched peers and are preferred in premenopausal women and men younger than 50. T scores are used in men aged 50 or older; BMD alone does not diagnose osteoporosis in a younger man.[8]
FRAX and Risk Stratification
The FRAX calculator integrates age, sex, BMI, and clinical risk factors to estimate 10-year probability of hip fracture and major osteoporotic fracture. It can be run with or without BMD input; adding femoral neck T score improves predictive accuracy.
Pharmacologic treatment is recommended for patients meeting any of the following thresholds:[1][7]
| Criterion | Threshold |
|---|---|
| Fragility fracture | Hip or vertebral fracture — treat regardless of T score |
| DXA T score | ≤ −2.5 at femoral neck, total hip, or lumbar spine |
| Osteopenia + FRAX | T score −1.0 to −2.5 and either 10-year hip fracture risk ≥3% or major osteoporotic fracture risk ≥20% (US-adapted FRAX) |
Risk is then stratified into high vs very high risk to guide agent selection (see Treatment below).
Screening and monitoring intervals
USPSTF 2025 supports screening women aged 65 or older and younger postmenopausal women at increased risk, but does not specify a single rescreening interval. Its average-risk screening framework does not replace evaluation of secondary osteoporosis or an existing fragility fracture.[2]
Separate repeat screening from treatment monitoring. Age, baseline BMD, new fractures, medication exposure and expected rate of change determine timing. Observational estimates of long intervals in older women with near-normal BMD should not be treated as a 10–15-year rule for every patient. BHOF suggests reassessment one to two years after starting or changing osteoporosis therapy, then individualized intervals.[4][5][6][9]
For ongoing systemic glucocorticoids, the American College of Rheumatology recommends risk assessment for adults taking ≥2.5 mg/day for more than three months, including BMD and vertebral assessment; reassessment is commonly every one to two years according to risk. This is distinct from the American College of Radiology imaging criteria.[10]
Treatment Overview
Full pharmacologic management is outside the scope of this article; the following framework supports risk stratification at the preventative-care visit.
High fracture risk
Agent choice depends on fractures, BMD, renal function, contraindications and adherence. Antiresorptives are commonly used:[1][7]
- Oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly) — first-line for most; low cost, extensive safety data.
- IV zoledronic acid 5 mg annually — preferred when adherence or GI tolerability is a concern.
- Denosumab 60 mg SC every six months — advanced CKD, especially dialysis or CKD-MBD, carries an FDA boxed warning for severe hypocalcemia and requires expert selection and monitoring. Do not present it as automatically safe in renal insufficiency. Avoid stopping or delaying without a plan for subsequent therapy because of rebound fracture risk.[12]
- Raloxifene (SERM) — modest vertebral benefit, no hip benefit; appropriate in younger postmenopausal women with breast cancer risk.
Very high fracture risk
Recent or multiple fractures, very low BMD and other major risk factors may favor an anabolic-first strategy. A remote single fracture does not automatically assign every patient to the same category:[1]
- Teriparatide — course duration and contraindications require specialist review, particularly with prior skeletal radiation or malignancy; avoid a blanket treatment algorithm for all cancer survivors.
- Romosozumab (anti-sclerostin) 210 mg SC monthly × 12 months — dual anabolic and antiresorptive; avoid in patients with recent MI or stroke.
- Follow with antiresorptive therapy after anabolic course to consolidate gains.
Calcium and vitamin D
Calcium 1,000–1,200 mg/day (dietary preferred over supplemental) and vitamin D 600–800 IU/day are adjuncts for all patients on pharmacologic therapy. Excess supplemental calcium (>1,000 mg/day from supplements) has been associated with cardiovascular risk in some cohorts.
GU-Specific Considerations
- Hormone exposure: Low-dose vaginal estrogen is not a treatment for osteoporosis. For GnRH therapy, follow the indication-specific label and assess individual bone risk rather than requiring the same add-back and DXA schedule for every short course.[11]
- Mobility and positioning: Review vertebral pain, falls, balance and ability to tolerate operative positioning. Avoid asserting that a vertebral fracture necessarily increases lumbar lordosis or directly worsens prolapse.
- Cancer survivors on AIs or ADT: Assess fracture risk and BMD, then choose bone-directed treatment according to risk and oncology context. ASCO generally supports DXA about every two years, with shorter intervals when clinically indicated; annual DXA and automatic antiresorptive co-treatment are not required for every patient.[14]
- Chronic systemic glucocorticoids: Use the dedicated rheumatology risk framework and reassess exposure, BMD, vertebral fractures and age. Do not apply a universal T-score −1.5 treatment trigger or assume chronic oral steroids are indicated for Hunner lesions.[10][13]
References
1. Walker MD, Shane E. "Postmenopausal Osteoporosis." N Engl J Med. 2023;389(21):1979–1991. doi:10.1056/NEJMcp2307353
2. US Preventive Services Task Force, Nicholson WK, Silverstein M, et al. "Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement." JAMA. 2025;333(6):498–508. doi:10.1001/jama.2024.27154
3. Curry SJ, Krist AH, Owens DK, et al. "Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement." JAMA. 2018;319(24):2521–2531. doi:10.1001/jama.2018.7498
4. White L. "Osteoporosis Prevention, Screening, and Diagnosis: ACOG Recommendations." Am Fam Physician. 2022;106(5):587–588.
5. Expert Panel on Musculoskeletal Imaging, Yu JS, Krishna NG, et al. "ACR Appropriateness Criteria® Osteoporosis and Bone Mineral Density: 2022 Update." J Am Coll Radiol. 2022;19(11S):S417–S432. doi:10.1016/j.jacr.2022.09.007
6. Plesa M, Wong A, Katsaggelos E. "Health Maintenance in Postmenopausal Women." Am Fam Physician. 2025;111(5):407–418.
7. Morin SN, Leslie WD, Schousboe JT. "Osteoporosis." JAMA. 2025;334(10):894–907. doi:10.1001/jama.2025.6003
8. ISCD. Official Adult Positions, 2023. BMD interpretation and follow-up.
9. LeBoff MS, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022. BHOF guidance.
10. Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res. 2023. doi:10.1002/acr.25240.
11. FDA. LUPRON DEPOT 11.25 mg prescribing information, 2025. Indication-specific duration and add-back.
12. FDA. Prolia: boxed warning for severe hypocalcemia in advanced CKD, 2024. Drug safety communication.
13. AUA. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome, 2022. Guideline.
14. Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. J Clin Oncol. 2019. doi:10.1200/JCO.19.01696.